Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Nbix | History Defined

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value

MarketBeat

3 Specialty Pharma Stocks Addressing Unmet Medical Needs

The specialty pharma sector is leading the charge in developing life-changing solutions for rare and chronic conditions. Amid this backdrop, investors might consider adding three fundamentally solid specialty pharma stocks, namely, Ipsen S.A. (IPSEY), ACADIA Pharmaceuticals (ACAD), and Neurocrine Biosciences (NBIX) in their portfolios. Read on….

StockNews.com

3 Top Growth Stocks to Buy at a Discount This Month

According to analysts, here are three top-notch mid-cap growth stocks to snag at a discount now.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Stocks to Buy for Potential Financial Fortunes

Amid surging medicine demand and ongoing drug shortages, the pharmaceutical industry thrives, driving improved patient outcomes and promising growth opportunities for investors. So, it could be wise to invest in quality pharma stocks ACADIA Pharmaceuticals (ACAD), Neurocrine Biosciences (NBIX), and Supernus Pharmaceuticals (SUPN), which can help you fetch potential financial…

StockNews.com

3 Pharma Stock Buys With Accelerating Gains

The pharmaceutical industry is expected to thrive as demand increases and technology advances. Therefore, fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), AstraZeneca (AZN) and Johnson & Johnson (JNJ) might be ideal additions to your portfolio for gains. Read on.

StockNews.com

Will These 3 Pharma Stocks Leave Investors Triumphant in 2024?

The pharmaceutical industry is undergoing a transformative shift driven by the advent of personalized drugs, technological innovations, and growing usage. Against this backdrop, does the inclusion of pharma stocks CytomX Therapeutics (CTMX), Merck & Co (MRK), and Neurocrine Biosciences (NBIX) in your portfolio appear wise? Let’s find out….

StockNews.com

Will These 3 Pharma Stocks Become Gainers in 2024?

The pharmaceutical sector is anticipated to prosper due to the strong demand for drugs and therapies and the adoption of advanced technologies. So, let’s analyze whether pharmaceutical stocks Kamada (KMDA), Neurocrine Biosciences (NBIX), and Novartis (NVS) are well positioned to capitalize on the industry’s growth prospects.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Pharma Powerhouses to Boost Your Year-End Investments

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

StockNews.com

Pharma Showdown: Evaluating Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX) Stock Performance Under the Microscope

The pharmaceutical landscape is evolving in response to the shift toward sedentary living and is driven by substantial investments in R&D and advanced technologies. Against this backdrop, which of the two pharma stocks, Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX), could generate better returns? Let’s find out….

StockNews.com

3 A-Rated Pharma Buys for October

The growing adoption of innovative drugs and the heightened demand for personalized medicines are expected to boost the pharma industry. Therefore, it might be wise to buy fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), Novo Nordisk (NVO), and AstraZeneca PLC (AZN), which are rated an A (Strong Buy) in our…

StockNews.com

3 A-Rated Pharma Stocks to Buy Today

The pharmaceutical industry is expected to grow in the upcoming years, propelled by continual advancements in medicine, aiming to meet the escalating demands for chronic disease treatment and address the needs of an aging population. Therefore, quality pharma stocks Neurocrine Biosciences (NBIX), AbbVie Inc. (ABBV), and Novo Nordisk A/S (NVO),…

StockNews.com

3 Pharma Stocks for Value Investors

The aging global population and the growing demand for drugs and therapies to treat chronic diseases are boosting the long-term prospects of the pharmaceutical industry. Amid this backdrop, value investors could consider buying fundamentally strong pharma stocks GSK plc (GSK), Horizon Therapeutics (HZNP), and Neurocrine Biosciences (NBIX), as they are…

StockNews.com

Healthy Returns: This A Rated Healthcare Stock Is a Must-Watch for May

Given the pharmaceutical industry’s robust growth prospects, drug-maker Neurocrine Biosciences’ (NBIX) stock is worth watching ahead of its first-quarter earnings next week. Read on….

StockNews.com

3 Hyper-Growth Stocks to Buy for Big Gains

With recent economic data showing promise, the chances of a soft landing for the economy are increasing. Hence, it could be wise to invest in fundamentally sound stocks CVS Health (CVS), Ooma (OOMA), and Neurocrine Biosciences (NBIX), which possess solid growth attributes. Read on….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Neurocrine Biosciences: Q1 Earnings Insights

Neurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga

Looking Into Neurocrine Biosciences's Return On Capital Employed

Benzinga Pro data, Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 sales of $312.00 million. Earnings fell to a loss of $7.30 million, resulting in a 132.44% decrease from last quarter.

Benzinga

Why Neurocrine Biosciences Are Trading Higher Today?

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.